EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on the Company’s proprietary NexACT® drug delivery technology, announced today that it has retained FTN Equity Capital Markets Corp., in New York City, as its financial advisor to assist the Company in exploring and evaluating strategic alternatives.
